Cingulate Sees Positive Results in Trial for ADHD Treatment
By Chris Wack Cingulate said it saw positive results from a Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301, for the treatment of...
Source: marketwatch.com
Global Impression Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Global Impression Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Global Impression Scale Today - Breaking & Trending Today
ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data - Cingulate (NASDAQ:CING)
Cingulate Inc (NASDAQ: CING) shares are trading lower after the company priced its $4-million public offering at around 58 cents per share
Source: benzinga.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Second Quarter 2023 Financial Results Conference Call. [Operator Instructions].
Source: insidermonkey.com
Could Low-Dose Ketamine Be a Treatment for ADNP Syndrome in Children?
Low-dose ketamine may be a viable treatment option for symptoms of activity-dependent neuroprotective protein syndrome in children.
Source: psychiatryadvisor.com
Could Low-Dose Ketamine Be a Treatment for ADNP Syndrome in Children?
Low-dose ketamine may be a viable treatment option for symptoms of activity-dependent neuroprotective protein syndrome in children.
Source: neurologyadvisor.com